Integrative multi-omic analysis reveals conserved cell-projection deficits in human Down syndrome brains.
Down syndrome
RNA-binding proteins
alternative splicing
axonogenesis
cell projection
miRNA
neurodevelopment
neuronal polarization
proteomics
transcriptomics
Journal
Neuron
ISSN: 1097-4199
Titre abrégé: Neuron
Pays: United States
ID NLM: 8809320
Informations de publication
Date de publication:
21 May 2024
21 May 2024
Historique:
received:
02
01
2023
revised:
17
03
2024
accepted:
01
05
2024
medline:
30
5
2024
pubmed:
30
5
2024
entrez:
29
5
2024
Statut:
aheadofprint
Résumé
Down syndrome (DS) is the most common genetic cause of cognitive disability. However, it is largely unclear how triplication of a small gene subset may impinge on diverse aspects of DS brain physiopathology. Here, we took a multi-omic approach and simultaneously analyzed by RNA-seq and proteomics the expression signatures of two diverse regions of human postmortem DS brains. We found that the overexpression of triplicated genes triggered global expression dysregulation, differentially affecting transcripts, miRNAs, and proteins involved in both known and novel biological candidate pathways. Among the latter, we observed an alteration in RNA splicing, specifically modulating the expression of genes involved in cytoskeleton and axonal dynamics in DS brains. Accordingly, we found an alteration in axonal polarization in neurons from DS human iPSCs and mice. Thus, our study provides an integrated multilayer expression database capable of identifying new potential targets to aid in designing future clinical interventions for DS.
Identifiants
pubmed: 38810652
pii: S0896-6273(24)00329-5
doi: 10.1016/j.neuron.2024.05.002
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests L.C. is cofounder/scientific consultant at IAMA Therapeutics. L.C. and A.C. are inventors on patents US9,822,368, EP3083959, JP6490077; US11427836; and IT102019000004929.